Eisai Europe Ltd. and Biogen Inc. announced today that a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback